The risk of PAH in patients with stage 3–5 CKD was estimated by calculating the scores corresponding to each risk factor (age, DM, Hb, PLT count, Scr, LVDd, LAD, MPAD, LVEF). This evidence concerns the gene GSTM1 and pulmonary arterial hypertension.